CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions

Cardiovasc Res. 2017 Sep 1;113(11):1376-1388. doi: 10.1093/cvr/cvx134.

Abstract

Aims: Lipid homeostasis is reprogrammed in the presence of inflammation, which results in excessive lipid accumulation in macrophages, and leads to the formation of lipid-laden foam cells. We aimed to link an inflammation-responsive transcription factor CCAAT/enhancer-binding protein delta (CEBPD) with polarized macrophages and dissect its contribution to lipid accumulation.

Methods and results: We found that CEBPD protein colocalized with macrophages in human and mouse (C57BL/6, Apoe-/-) atherosclerotic plaques and that Cebpd deficiency in bone marrow cells suppressed atherosclerotic lesions in hyperlipidemic Apoe-/- mice. CEBPD was responsive to modified low-density lipoprotein (LDL) via the p38MAPK/CREB pathway, and it promoted lipid accumulation in M1 macrophages but not in M2 macrophages. CEBPD up-regulated pentraxin 3 (PTX3), which promoted the macropinocytosis of LDL, and down-regulated ATP-binding cassette subfamily A member 1 (ABCA1), which impaired the intracellular cholesterol efflux in M1 macrophages. We further found that simvastatin (a HMG-CoA reductase inhibitor) could target CEBPD to block lipid accumulation in a manner not directly related to its cholesterol-lowering effect in M1 macrophages.

Conclusion: This study underscores how CEBPD functions at the junction of inflammation and lipid accumulation in M1 macrophages. Therefore, CEBPD-mediated lipid accumulation in M1 macrophages could represent a new therapeutic target for the treatment of cardiovascular diseases.

Keywords: CEBPD; Inflammation; Macrophages; PTX3; Statins.

MeSH terms

  • ATP Binding Cassette Transporter 1 / genetics
  • Animals
  • Atherosclerosis / drug therapy
  • Atherosclerosis / metabolism
  • CCAAT-Enhancer-Binding Protein-delta / metabolism*
  • Cholesterol / metabolism
  • Foam Cells / drug effects
  • Foam Cells / metabolism*
  • Homeostasis / drug effects
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hypercholesterolemia / drug therapy
  • Hypercholesterolemia / metabolism
  • Lipid Metabolism
  • Lipoproteins, LDL / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Up-Regulation

Substances

  • ATP Binding Cassette Transporter 1
  • CEBPD protein, human
  • Cebpd protein, mouse
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, LDL
  • CCAAT-Enhancer-Binding Protein-delta
  • Cholesterol